The purpose of the study was to identify factors that could predict good yields of peripheral blood stem cells (PBSC) in multiple myeloma (MM). Fifty-one MM patients, nine with refractory disease and 42 in plateau phase, were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m 2 followed by granulocyte colonystimulating factor (G-CSF) 5 g/kg/day. Clinical and laboratory parameters at the time of mobilization were analyzed for correlations with the number of CD34 + cells collected, with the colony-forming unit granulocyte-macrophage (CFU-GM) count, and the mononuclear cell (MNC) count. In univariate analysis, low WBC count, low platelet count, prior exposure to melphalan, and an interval Ͼ6 months from the start of treatment correlated with poor yields of CD34 + cells. Low platelet count, prior exposure to melphalan or to radiotherapy, and an interval Ͼ6 months from the start of treatment were associated with a low CFU-GM count. On the basis of these data, we defined a scoring system able to predict the yield of the mobilizing procedure. According to this system, the presence of more than one risk factor (low WBC and platelet counts, prior exposure to melphalan, interval from first chemotherapy Ͼ6 months) was predictive of insufficient collections when a conventional combination of mobilizing measures are used. Bone Marrow Transplantation (2000) 26, 283-286. 
Survival of patients with multiple myeloma (MM) has been improved by adopting high-dose regimens 1,2 which usually include one or two autologous transplants after conditioning with high-dose melphalan. To restore hematopoiesis, peripheral blood stem cells (PBSC) are mostly used due to ease of collection and the more rapid engraftment compared with bone marrow. 3 A combination of high-dose cyclophosphamide and hematopoietic growth factors (G-CSF or GM-CSF) is the most common approach to mobilizing 4, 5 therapy or growth factors 6, 7 used as single agents. Recent observations support the use of G-CSF alone used at higher dosage, particularly in heavily treated cancer patients. [8] [9] [10] [11] Since the number of CD34 + stem cells has been shown to be the most important factor for a rapid hematological reconstitution, many studies have tried to establish their optimal dose. A number ranging between 2.0 and 5.0 × 10 6 /kg seems adequate for a good engraftment, [12] [13] [14] with a threshold of Ͼ1.0 × 10 6 in patients without extensive prior chemoradiotherapy and у2 × 10 6 in all others. 15 Another crucial aspect is the identification of factors predictive of an adequate yield of CD34 + stem cells. These factors would be useful to define the optimal timing and the best combination of mobilizing agents. Among the factors analyzed at the time of mobilization, the extent of prior chemotherapy, exposure to alkylating agents and/or to radiation therapy, and bone marrow infiltration, seem to affect negatively the CD34 + cell harvest. 12, [14] [15] [16] [17] [18] [19] Most of these studies, however, are performed on mixed cohorts of cancer patients affected by lymphoproliferative diseases (lymphomas and myelomas) as well as by acute leukemias or solid tumors. In fact, very few studies are devoted exclusively to multiple myeloma patients. So, important issues remain to be clarified: eg the optimum timing for mobilization, the choice of mobilization agents, the mobilizing strategy for previously treated patients and for the so called poor mobilizers.
progenitor cells (PBSC). It gives better results than chemo-
The aim of this study was to identify, in a homogeneous MM population, which clinical and laboratory features may affect the mobilization of a sufficient number of progenitor cells when standard mobilizing procedures are used.
Materials and methods

Patients
Between 1995 and 1999, 51 MM patients (31 males, 20 females) entered the study. The median age was 49 years (range 31-61). Patients were staged by Durie and Salmon's classification: 15 patients were in stage I and 36 in stage II. At the time of mobilization nine patients had refractory disease, and 42 were in stable phase. Of 51 patients, 19 (37%) had been treated with alkylating agents, 29 (57%) with VAD-based regimens only, three were previously untreated, and nine (17%) had received local radiotherapy. Skeletal lesions were scored as follows: 0 no lesions, 1 osteoporosis, 2 one or two lesions, 3 more than two lesions, and 4 fractures or vertebral crushing. Twenty-eight patients Bone Marrow Transplantation (55%) had skeletal lesions. In order to identify factors that correlated with the number of CD34 + cells, the colonyforming unit granulocyte-macrophage (CFU-GM) count and the mononuclear cell count (MNC), the following clinical and laboratory parameters and the therapeutic history of the patients were recorded: stage, phase of disease, interval from start of treatment to the time of mobilization, previous exposure to alkylating agents or radiotherapy, type of M component, Bence Jones proteinuria, skeletal involvement (analyzed as dichotomous variables), age, WBC and platelet counts, hemoglobin level, LDH, bone marrow plasmacytosis, creatinine, urea (analyzed as continuous variables). All these parameters were evaluated at time of mobilization.
Mobilization and collection of progenitor cells
Patients were mobilized with high-dose cyclophosphamide (HD-Cy) 4 g/m 2 followed by hematopoietic growth factor (G-CSF 5 g/kg/day) started 48 h after chemotherapy. The first collection was performed when the number of peripheral blood CD34
+ cells reached a count of at least 20/l. A median of 2 (range 1-6) daily leukaphereses were performed after a median time of 10 days from the beginning of mobilization chemotherapy (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . PBSC were collected with a continuous-flow blood cell separator Spectra (COBE BCT, Lakewood, CO, USA) processing a total volume per leukapheresis of 2-3 blood volumes.
Flow cytometry
Aliquots of the leukapheresis products were incubated with phycoerythin-conjugated monoclonal anti-CD34 (HPCA2; Becton Dickinson, San Jose, CA, USA) for 15 min at 20°C, then lysed with a lyse-no-wash standard assay and finally incubated for 10 min at 4°C. Cells were processed with a FACSort analyzer (Becton Dickinson). Data acquisition was performed with Cellquest software (Becton Dickinson).
CFU-GM assays
Hematopoietic progenitors were grown in methylcellulose (Methocult Stemcell Technologies, Vancouver, BC, Canada) supplemented with leukocyte conditioned medium (10% final concentration) (Hemostim-Terry Fox, Technologies, Vancouver, BC, Canada) and rHu Epo (Eprex-Cilag, Janssen-Cilag, Milan, Italy) 4 U/ml. Cultures were incubated at 37°C in humidified 5% CO 2 . Formation of CFU-GM, burst-forming unit erythroid (BFU-E) and colonies of multiple lineages (CFU-mix) were scored on day 14.
Cryopreservation
Cells in 20% dimethylsulfoxide (DMSO, Lagitre, Milan, Italy) were frozen to −160°C by means of a KRYO II Series freezer (Planer R203) (Planer Products, Middlesex, UK) at a controlled rate and then stored in the liquid phase of nitrogen.
Statistical analysis
Continuous data were described as median and range. Categorical data were reported as count and relative frequency. For the purpose of the analysis all the continuous variables were log-transformed, to reduce dispersion of values. The association of the above-mentioned clinical and laboratory parameters with the number of CD34 + cells, the CFU-GM and the MNC was assessed by means of
The Mann-Whitney U test was used to compare the number of CD34
+ cells between scores. No multivariate analysis was performed due to the small number of patients. All tests were two-tailed; P Ͻ 0.05 was considered to be statistically significant. Stata 6.0 (Stata Corp, College Station, TX, USA) was used for computation.
Results
The characteristics and the previous therapeutic history of the 51 MM patients at time of mobilization are described in Table 1 . As shown, no patients had renal insufficiency, the majority of patients were in stable phase and very few presented with advanced disease. Of 51 patients, 17 (33%) had been treated at the onset with melphalan. The median interval from the start of first chemotherapy to the date of mobilization was 4 months (range 0-81).
The characteristics of the leukaphereses are detailed in Table 2 . A total of 111 leukaphereses were performed after 57 mobilizing procedures in 51 patients, with the aim of collecting at least 2 × 10 6 CD34 + cells/kg, and with a target value of 4 × 10 6 CD34 + cells/kg when possible. Sufficient numbers of progenitors (Ͼ2 × 10 6 CD34 + cells/kg) were collected in 40 patients (78%). In 33 (65%) the target of 4 , and seven g/m 2 in the others). Four of six patients failed again and no further mobilizations were attempted. The levels of circulating CD34
+ cells significantly correlated with the total CD34 + cells obtained with the respective leukapheresis (P = 0.001).
Factors influencing progenitor cell collection
As reported above, several clinical and laboratory parameters were analyzed for their correlation with the number of CD34
+ cells, the CFU-GM count and the MNC count. In univariate analysis, low WBC count (P = 0.005), low platelet count (P = 0.01), prior exposure to melphalan (P = 0.03), and an interval Ͼ6 months from the start of treatment (P = 0.01) were correlated with poor yields of CD34 + cells. Low platelet count (P = 0.04), prior exposure to melphalan (P = 0.03) or to radiotherapy (P = 0.03), and interval Ͼ6 months from the start of treatment (P = 0.04) were associated with a low CFU-GM count. In contrast, only the percentage of bone marrow plasma cells had a strong correlation with the MNC count (P = 0.02). We also correlated the same parameters with the numbers of CD34 + cells keeping the limit of 2 × 10 6 /kg CD34 + cells as a cut-off. Lower platelet count (P = 0.04), exposure to alkylating agents (P = 0.03), interval Ͼ6 months (P = 0.009), and older age (P = 0.05) were found to be associated with a CD34 + yield below the 2 × 10 6 /kg CD34 + cell cut-off. On the basis of the factors negatively associated with the number of CD34 + cells collected (lower WBC or platelet count, prior exposure to melphalan, interval Ͼ6 months from the start of treatment), patients were scored as having 0, 1, 2, 3 or 4 risk factors. Patients presenting at mobilization with two or more risk factors had a significantly lower median number of CD34 + progenitor cells (3.60 vs 7.06 × 10 6 /kg CD34 + cells; P = 0.007). Figure 1 shows the probability of collecting insufficient number of progenitor cells according to the presence of 0, 1, 2, 3 or 4 risk factors.
Discussion
Autologous transplantation has a central role in the treatment of multiple myeloma, and PBSC are the main source of progenitor cells used to restore hemopoiesis after conditioning. Several aspects, however, remain controversial, Bone Marrow Transplantation ie which factors can be considered predictors of insufficient collections of CD34 + stem cells, how to optimize the mobilizing therapy and how to manage poor mobilizers. The aim of this study was to define whether previous therapeutic history and the clinical and laboratory parameters evaluated at the time of mobilization somehow correlated with the number of progenitor cells harvested. Although the number of patients entering this study was not large, the group was homogeneous and all patients received the same combination of cyclophosphamide and G-CSF at fixed dosages.
The WBC count and the platelet count correlated significantly with the number of CD34 + stem cells harvested. This finding supports previous studies reporting the reliability of these parameters as predictors of bone marrow efficiency. Krieger et al 20 for instance, demonstrated that collection of stem cells based on the rising WBC and platelet count increases the number of CD34 + cells in the leukapheresis product in comparison to collection on a fixed day. Ketterer et al 19 reported that a platelet value higher than 150 × 10 9 /l correlates significantly with successful mobilizations. In our analysis, the platelet count influenced the number of CFU-GM as well.
In accordance with other authors 14, 17, 19, 21 we observed that prior exposure to melphalan substantially affects the probability of obtaining adequate collections of progenitor cells both in terms of CD34 + cells and of CFU-GM. Several authors also emphasized the importance of the exposure time, reporting variable periods ranging between 6 and 9 months. 14, 19 Our analysis with a period of 6 months is in line with these studies. The importance of prior radiotherapy and of marrow involvement are variously reported in the literature as factors negatively affecting the yield. 12, 16, 18, 19 In this study, radiotherapy was significantly related to the number of CFU-GM but not with the CD34 + cells. This controversial result could be related to the low number of patients exposed to radiotherapy. Probably for the same reason, bone marrow plasmacytosis correlated only with the MNC count. Age reached statistical significance only when a cut-off for the CD34 + cells was used for the analysis.
The identification of risk factors of poor peripheral blood stem cell collection in MM patients is of clinical relevance for therapeutic decisions. It could allow the definition of mobilizing strategies tailored to the characteristics of patients. The analysis reported here demonstrates that the presence of more than one negative factor entails a substantial risk of inadequate collection. In these subset of patients mobilizing protocols including G-CSF at higher dosage 13 or in combination with SCF 22 could be of value.
